# Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis

> **NCT03049267** · PHASE2 · COMPLETED · sponsor: **M.B.A. van Doorn** · enrollment: 20 (actual)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** Apremilast
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03049267
- **Lead sponsor:** M.B.A. van Doorn
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-02
- **Primary completion:** 2017-12-06
- **Final completion:** 2018-06-28
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-07-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03049267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03049267, "Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03049267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*